Familial Cancer

, Volume 12, Issue 3, pp 397–402 | Cite as

Diagnosis and management of BHD-associated kidney cancer

  • Lambros Stamatakis
  • Adam R. Metwalli
  • Lindsay A. Middelton
  • W. Marston Linehan
Original Article


In addition to the associated cutaneous and pulmonary manifestations, individuals with the Birt-Hogg-Dubé (BHD) syndrome have an increased risk of developing kidney cancer, which is often bilateral and multifocal. The risk of developing a renal tumor in this population does not decrease with age and therefore warrants a lifelong screening approach. We recommend abdominal imaging every 36 months in individuals without renal lesions at initial screening. Once renal tumors are identified, they should be followed with interval imaging studies until the largest tumor reaches 3 cm in maximal diameter, at which point nephron-sparing surgery should be ideally pursued. While the histology of renal tumors can vary in the BHD syndrome, most tumors possess a relatively indolent natural history and do not require adjuvant therapy if resected when localized to the kidney. With this approach, the vast majority of patients will achieve a curative oncologic outcome and avoid the medical sequelae of chronic renal insufficiency that could otherwise result from total nephrectomy.


Birt-Hogg-Dubé Clinical Management Syndrome Kidney cancer BHD Renal cell carcinoma 


  1. 1.
    Birt AR, Hogg GR, Dube WJ (1977) Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 113:1674–1677PubMedCrossRefGoogle Scholar
  2. 2.
    Chung JY, Ramos-Caro FA, Beers B, Ford MJ, Flowers F (1996) Multiple lipomas, angiolipomas, and parathyroid adenomas in a patient with Birt-Hogg-Dube syndrome. Int J Dermatol 35:365–367PubMedCrossRefGoogle Scholar
  3. 3.
    Roth JS, Rabinowitz AD, Benson M, Grossman ME (1993) Bilateral renal cell carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 29:1055–1056PubMedCrossRefGoogle Scholar
  4. 4.
    Toro JR, Glenn G, Duray P, Darling T, Weirich G, Zbar B et al (1999) Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 135:1195–1202PubMedCrossRefGoogle Scholar
  5. 5.
    Zbar B, Alvord WG, Glenn G, Turner M, Pavlovich CP, Schmidt L et al (2002) Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 11:393–400PubMedGoogle Scholar
  6. 6.
    Schmidt LS, Warren MB, Nickerson ML, Weirich G, Matrosova V, Toro JR et al (2001) Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69:876–882PubMedCrossRefGoogle Scholar
  7. 7.
    Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn GM, Turner ML et al (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2:157–164PubMedCrossRefGoogle Scholar
  8. 8.
    Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA et al (2005) High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst 97:931–935PubMedCrossRefGoogle Scholar
  9. 9.
    Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocke C et al (2008) BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet 45:321–331PubMedCrossRefGoogle Scholar
  10. 10.
    Pavlovich CP, Grubb RL III, Hurley K, Glenn GM, Toro J, Schmidt LS et al (2005) Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 173:1482–1486PubMedCrossRefGoogle Scholar
  11. 11.
    Shuch B, Singer EA, Bratslavsky G (2012) The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin North Am 39:133–148, vGoogle Scholar
  12. 12.
    Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR Jr et al (2007) Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 178:41–46PubMedCrossRefGoogle Scholar
  13. 13.
    Kowalczyk KJ, Hooper HB, Linehan WM, Pinto PA, Wood BJ, Bratslavsky G (2009) Partial nephrectomy after previous radio frequency ablation: the national cancer institute experience. J Urol 182:2158–2163PubMedCrossRefGoogle Scholar
  14. 14.
    Nguyen CT, Campbell SC (2008) Salvage of local recurrence after primary thermal ablation for small renal masses. Expert Rev Anticancer Ther 8:1899–1905PubMedCrossRefGoogle Scholar
  15. 15.
    Wile GE, Levendecker JR, Krenbiel KA, Dyer RB, Zagoria RJ (2013) CT and MR imaging after imaging-guided thermal ablation of renal neoplasms. Radiographics 27:325–329CrossRefGoogle Scholar
  16. 16.
    Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM et al (2002) Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26:1542–1552PubMedCrossRefGoogle Scholar
  17. 17.
    Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ et al (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 76:1023–1033PubMedCrossRefGoogle Scholar
  18. 18.
    Benhammou JN, Vocke CD, Santani A, Schmidt LS, Baba M, Seyama K et al (2011) Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dube syndrome. Genes Chromosomes Cancer 50:466–477PubMedCrossRefGoogle Scholar
  19. 19.
    Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A et al (2006) Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA 103:15552–15557PubMedCrossRefGoogle Scholar
  20. 20.
    Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M et al (2008) Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 415:60–67PubMedCrossRefGoogle Scholar
  21. 21.
    Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME et al (2009) Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci USA 106:18722–18777PubMedCrossRefGoogle Scholar
  22. 22.
    Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP et al (2010) Molecular diagnosis and therapy of kidney cancer. Ann Rev Med 61:329–343PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht (outside the USA) 2013

Authors and Affiliations

  • Lambros Stamatakis
    • 1
  • Adam R. Metwalli
    • 1
  • Lindsay A. Middelton
    • 1
  • W. Marston Linehan
    • 1
  1. 1.Urologic Oncology Branch, Center for Cancer ResearchNational Cancer InstituteBethesdaUSA

Personalised recommendations